Pankreaserkrankungen – Update
2011

J Ringel; M M Lerch; J Mayerle

doi:10.1055/s-0031-1286389

DMW – Klinischer Fortschritt, Table of Contents

Dtsch Med Wochenschr 2011; 136(40): 2037-2039
DOI: 10.1055/s-0031-1286389

Verdauungs- und Stoffwechselkrankheiten | Commentary

Gastroenterologie
© Georg Thieme Verlag KG Stuttgart · New York

Pankreaserkrankungen – Update 2011

Pancreatic diseases: update 2011J. Ringel¹ , M. M. Lerch¹ , J. Mayerle¹

¹Klinik für Innere Medizin A, Universitätsmedizin der Ernst-Moritz-Arndt-Universität, Greifswald

Abstract

Schlüsselwörter

pankreopriver Diabetes - Pankreaskarzinom - Autoimmunpankreatitis

Keywords

pancreatogenic diabetes - pancreatic cancer - autoimmune pancreatitis

Full Text

References

Literatur

1 Artinyan A, Anaya D A, McKenzie S. et al . Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer. 2011; 117 2044-2049
2 Conroy T, Desseigne F, Ychou M. et al . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364 1817-1825
3 Cui Y F, Andersen D K. Pancretogenic diabetes: Special considerations for management. Pancreatology . 2011; 11 279-294
4 Elashoff M, Matveyenko A V, Gier B, Elashoff R, Butler P C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141 150-156
5 Hsu C, Saif M. Diabetes and pancreatic cancer – highlights from the „2011 ASCO Annual Meeting“. Chicago, IL, USA; June 3 – 7,2011. J Pancreas. 2011; 12 330-333
6 Moore M J, Goldstein D, Hamm J. et al . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25 1960-1966
7 Neoptolemos J P, Stocken D D, Bassi C. et al . Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304 1073-1081
8 Pelzer U, Schwaner I, Stieler J. et al . Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group. Eur J Cancer. 2011; 47 1676-1681
9 Pisa A. The effect of time to adjuvant chemotherapy on survivial in nonmetastatic resectable pancreatic pancreatic cancer: A retrospective analysis. J Clin Oncol. 2011; 29 (Suppl) e14519
10 Sahora K, Kuehrer I, Eisenhut A. et al . NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advavanced, nonmetastasized pancreatic cancer. Surgery. 2011; 149 311-320
11 Shimosegawa T, Chari S T, Frukkoni L. et al . International consensus diagnostic criteria for autoimmune pancreatitis. Pancreas. 2011; 40 352-358

Prof. Dr. Markus M. Lerch

Klinik für Innere Medizin A
Universitätsmedizin
Ernst-Moritz-Arndt-Universität Greifswald

Friedrich-Loeffler-Str. 23a

17475 Greifswald

Phone: 03834/86-7230

Fax: 03834/86-7234

Email: lerch@uni-greifswald.de